Published in Magn Reson Med on January 01, 2005
Sodium and T1rho MRI for molecular and diagnostic imaging of articular cartilage. NMR Biomed (2006) 2.48
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia (2006) 2.30
Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer (2006) 1.54
Biomedical applications of sodium MRI in vivo. J Magn Reson Imaging (2013) 1.02
Sodium and proton diffusion MRI as biomarkers for early therapeutic response in subcutaneous tumors. Magn Reson Imaging (2006) 0.99
Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance. NMR Biomed (2006) 0.97
Sodium MRI: methods and applications. Prog Nucl Magn Reson Spectrosc (2014) 0.93
Application of 23Na MRI to monitor chemotherapeutic response in RIF-1 tumors. Neoplasia (2005) 0.87
Using magnetic resonance imaging and spectroscopy in cancer diagnostics and monitoring: preclinical and clinical approaches. Cancer Biol Ther (2011) 0.86
In vivo magnetic resonance imaging of sodium and diffusion in rat glioma at 21.1 T. Magn Reson Med (2011) 0.84
Sodium-23 magnetic resonance imaging has potential for improving penumbra detection but not for estimating stroke onset time. J Cereb Blood Flow Metab (2014) 0.79
Chemically induced breast tumors in rats are detectable in early stages by contrast enhanced magnetic resonance imaging but not by changes in the acute-phase reactants in serum. Int J Mol Sci (2011) 0.75
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst (2000) 5.14
Image formation by induced local interactions. Examples employing nuclear magnetic resonance. 1973. Clin Orthop Relat Res (1989) 4.59
MRI of the tumor microenvironment. J Magn Reson Imaging (2002) 2.87
Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther (2003) 2.28
Molecular imaging and cancer. Mol Cancer Ther (2003) 1.98
Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MRI study. Proc Natl Acad Sci U S A (1998) 1.91
Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology (2003) 1.77
Brain tissue sodium is a ticking clock telling time after arterial occlusion in rat focal cerebral ischemia. Stroke (2000) 1.68
Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging (2002) 1.53
Comprehensive MR imaging protocol for stroke management: tissue sodium concentration as a measure of tissue viability in nonhuman primate studies and in clinical studies. Radiology (1999) 1.42
Uncoupling cell shrinkage from apoptosis reveals that Na+ influx is required for volume loss during programmed cell death. J Biol Chem (2003) 1.36
Quantifying sodium in the human wrist in vivo by using MR imaging. Radiology (2002) 1.24
Quantitative tissue sodium concentration mapping of normal rat brain. Magn Reson Med (1996) 1.20
Quantitative tissue sodium concentration mapping of the growth of focal cerebral tumors with sodium magnetic resonance imaging. Magn Reson Med (1999) 1.18
Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging. Clin Cancer Res (2000) 1.18
Human skeletal muscle: sodium MR imaging and quantification-potential applications in exercise and disease. Radiology (2000) 1.17
Spectrally weighted twisted projection imaging: reducing T2 signal attenuation effects in fast three-dimensional sodium imaging. Magn Reson Med (1997) 1.06
Methodology of in vivo human sodium MR imaging at 1.5 T. Radiology (1986) 1.03
Overview of targeted therapies for cancer. Am J Health Syst Pharm (2003) 1.03
MR imaging of sodium in the human brain with a fast three-dimensional gradient-recalled-echo sequence at 4 T. Acad Radiol (2003) 1.03
In vivo Na-23 MR imaging and spectroscopy of rat brain during TmDOTP5- infusion. J Magn Reson Imaging (1992) 1.01
TmDOTP(5-) as a (23)Na shift reagent for the subcutaneously implanted 9L gliosarcoma in rats. Magn Reson Med (2001) 0.93
Effects of chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea on single-quantum- and triple-quantum-filtered 23Na and 31P nuclear magnetic resonance of the subcutaneously implanted 9L glioma. Cancer Res (2001) 0.93
Postictal alteration of sodium content and apparent diffusion coefficient in epileptic rat brain induced by kainic acid. Epilepsia (1996) 0.89
Sodium-23 magnetic resonance brain imaging. Neuroradiology (1990) 0.89
Direct, longitudinal comparison of (1)H and (23)Na MRI after transient focal cerebral ischemia. Stroke (2001) 0.88
Sodium overload through voltage-dependent Na(+) channels induces necrosis and apoptosis of rat superior cervical ganglion cells in vitro. Brain Res Bull (2000) 0.86
Role of nuclear magnetic resonance spectroscopy (MRS) in cancer diagnosis and treatment: 31P, 23Na, and 1H MRS studies of three models of pancreatic cancer. Cancer Res (1997) 0.85
Targeting apoptosis in cancer chemotherapy. Expert Opin Ther Targets (2002) 0.85
Triple-quantum-filtered (23)Na NMR spectroscopy of subcutaneously implanted 9l gliosarcoma in the rat in the presence of TmDOTP(5-1). J Magn Reson (2001) 0.85
Fast three-dimensional sodium imaging of human brain. MAGMA (2001) 0.84
Molecular imaging of gliomas. Mol Imaging (2002) 0.83
Altered nuclear localization of bax protein in BCNU-resistant glioma cells. J Neurooncol (2000) 0.82
TmDOTP5- as a 23Na shift reagent for the in vivo rat kidney. Magn Reson Med (1995) 0.80
Molecular imaging: new applications for biochemistry. J Cell Biochem Suppl (2002) 0.79
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia (2011) 5.53
Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A (2005) 4.63
Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med (2010) 4.15
CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A (2007) 3.85
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15
Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials (2007) 3.12
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol (2010) 2.90
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience. Radiology (2005) 2.69
It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging (2002) 2.58
Towards hyperpolarized (13)C-succinate imaging of brain cancer. J Magn Reson (2007) 2.57
Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology (2012) 2.53
Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res (2006) 2.46
Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol (2007) 2.39
The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med (2009) 2.32
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia (2006) 2.30
Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther (2003) 2.28
PASADENA hyperpolarization of succinic acid for MRI and NMR spectroscopy. J Am Chem Soc (2008) 2.27
A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol (2009) 2.10
MRI-guided prostate radiation therapy planning: Investigation of dosimetric accuracy of MRI-based dose planning. Radiother Oncol (2011) 2.09
Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A (2002) 1.93
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys (2005) 1.79
In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther (2003) 1.77
Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci (2003) 1.72
Molecular imaging of Akt kinase activity. Nat Med (2007) 1.68
Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev (2006) 1.66
A methodology for registration of a histological slide and in vivo MRI volume based on optimizing mutual information. Mol Imaging (2006) 1.63
Multi-system repeatability and reproducibility of apparent diffusion coefficient measurement using an ice-water phantom. J Magn Reson Imaging (2012) 1.57
PASADENA hyperpolarization of 13C biomolecules: equipment design and installation. MAGMA (2008) 1.56
Hyperpolarized water as an MR imaging contrast agent: feasibility of in vivo imaging in a rat model. Radiology (2012) 1.54
Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol (2005) 1.54
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging (2002) 1.53
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50
Diffusion coefficient measurement using a temperature-controlled fluid for quality control in multicenter studies. J Magn Reson Imaging (2011) 1.50
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res (2007) 1.48
Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A (2005) 1.44
AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A (2009) 1.43
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res (2004) 1.42
Quality assurance of PASADENA hyperpolarization for 13C biomolecules. MAGMA (2008) 1.41
Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging (2006) 1.40
Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res (2011) 1.39
Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys (2008) 1.39
The immunogenicity and efficacy against H5N1 challenge of reverse genetics-derived H5N3 influenza vaccine in ducks and chickens. Virology (2006) 1.39
Diffusion imaging for therapy response assessment of brain tumor. Neuroimaging Clin N Am (2009) 1.38
Real-time molecular imaging of tricarboxylic acid cycle metabolism in vivo by hyperpolarized 1-(13)C diethyl succinate. J Am Chem Soc (2011) 1.36
Real-time evaluation of p53 oscillatory behavior in vivo using bioluminescent imaging. Cancer Res (2006) 1.34
Characterization of pancreatic tumor motion using cine MRI: surrogates for tumor position should be used with caution. Int J Radiat Oncol Biol Phys (2009) 1.34
Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res (2007) 1.31
Pathogenicity and vaccine efficacy of different clades of Asian H5N1 avian influenza A viruses in domestic ducks. J Virol (2008) 1.30
Registration methodology for histological sections and in vivo imaging of human prostate. Acad Radiol (2008) 1.30
Parahydrogen-induced polarization (PHIP) hyperpolarized MR receptor imaging in vivo: a pilot study of 13C imaging of atheroma in mice. NMR Biomed (2011) 1.27
Reduced glutamate neurotransmission in patients with Alzheimer's disease -- an in vivo (13)C magnetic resonance spectroscopy study. MAGMA (2003) 1.26
An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res (2007) 1.26